Cardlytics (CDLX) Q2 2024 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 2024 earnings summary
2 Feb, 2026Executive summary
COO Amit Gupta appointed as CEO effective August 16, 2024, succeeding Karim Temsamani.
Revenue for Q2 2024 was $69.6 million, down 9% year-over-year, with billings up 1% to $110.4 million, reflecting strong advertiser demand but offset by higher consumer incentives.
Net loss narrowed to $4.3 million from $23.5 million in Q2 2023, aided by a $13.0 million gain on debt extinguishment and a $5.8 million gain from contingent consideration settlement.
Monthly active users (MAUs) grew 3% year-over-year to 165.5 million, but ARPU declined 13% to $0.42 due to increased consumer incentives.
The company is in the early stages of a significant transformation, focusing on technology modernization and operational improvements.
Financial highlights
Q2 2024 billings were $110.4 million, up 2% year-over-year excluding the former Entertainment subsidiary.
Revenue was $69.6 million, down 9% year-over-year, due to under-delivery of advertiser budgets and higher consumer incentives.
Adjusted contribution was $36.4 million, nearly flat year-over-year, with a margin of 52%.
Adjusted EBITDA improved to a loss of $2.3 million from a $4.1 million loss in Q2 2023.
Consumer incentives increased 25% to $40.8 million, reflecting higher engagement.
Operating cash flow was $4.4 million; free cash flow was -$0.4 million.
Ended Q2 with $71.2 million in cash and $60 million in unused credit.
Outlook and guidance
Q3 2024 guidance: billings of $100–$106 million, revenue of $56–$63 million, adjusted contribution of $32–$35 million, and adjusted EBITDA of -$6 to -$3.5 million.
No expectation for double-digit billings growth or positive operating cash flow for full year 2024.
2025 expected to see performance acceleration, double-digit billings growth, and positive free cash flow as operational execution improves and new partnerships scale.
Year-over-year declines expected in all major metrics for Q3, reflecting ongoing transition and market headwinds.
Latest events from Cardlytics
- Revenue and billings fell, but operational gains and U.K. growth support optimism for 2026.CDLX
Q4 20254 Mar 2026 - Q3 revenue fell 15% to $67.1M, with a $145M net loss from impairment charges.CDLX
Q3 202416 Jan 2026 - Q4 beat guidance despite a 10% revenue drop; 2025 targets sequential gains and profitability.CDLX
Q4 202424 Dec 2025 - Proxy covers director elections, auditor ratification, new equity plan, and executive pay reforms.CDLX
Proxy Filing1 Dec 2025 - Proxy update adds XBRL tagging and details strict insider trading and equity award policies.CDLX
Proxy Filing1 Dec 2025 - Preliminary proxy statement outlines voting matters and governance, with no major capital changes.CDLX
Proxy Filing1 Dec 2025 - Revenue dropped 8.4% but net loss narrowed as user base grew and cost controls took effect.CDLX
Q1 202526 Nov 2025 - Q2 revenue fell 9% as billings and net loss worsened; Q3 billings to drop 15%-22%.CDLX
Q2 202523 Nov 2025 - Revenue and billings dropped, but net loss narrowed and user growth remained strong.CDLX
Q3 202513 Nov 2025